1 Morgan Stanley, Could Obesity Drugs Take a Bite Out of the Food Industry, 2023 2 Morgan Stanley, 2023 3 The Food Institute, 2024 4 Nestle, First-to-market Vital Pursuit Hits Shelves Nationwide, 2024 5 Grocery Dive, How GLP-1s Could Reshape the Grocery Store, 2025 6 MediaRadar, Weight Loss, Diabetes Drug Ad Spending Tops $1B, 2024 7 McKinsey, What are GLP-1 Medications?, 2025 8 JP Morgan Research, The Increase in Appetite for Obesity Drugs, 2023 9 Cornell University, The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand, 2024
Since tolerance did not develop with applications of PYY3-36, it is reasonable to assume that this peptide (similar to PP, but opposite to leptin) has potential in long-term obesity therapy
So if you're considering semaglutide while breastfeeding, the injectable forms appear to be safer options based on current evidence
The report also revealed something concerning: many children and teens are being prescribed Ozempic for weight loss, despite it not being approved in children for Type 2 diabetes or weight management
For type 2 diabetes management , NICE guideline NG28 recommends GLP-1 receptor agonists as a treatment option when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI of 35 kg/m or higher (or lower thresholds for people from South Asian and related minority ethnic backgrounds) Weight loss would benefit other obesity-related comorbidities Continuation of GLP-1 therapy for diabetes typically requires demonstration of beneficial response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months
